The DOI matches its Crossref record; 35 of the 36 references it cites were found in a registry or an index.
Loss of Cdk2 and cyclin A2 impairs cell proliferation and tumorigenesis.
Open accessPublished version of a preprint
Abstract
Cell-cycle inhibition has yet to offer a generally effective approach to cancer treatment, but a full evaluation of different combinations of cell-cycle inhibitors has not been evaluated. Cyclin A2, a core component of the cell cycle, is often aberrantly expressed in cancer where it may impact cell proliferation. In this study, we investigated the role of cyclin A2 in tumorigenesis using a conditional genetic knockout mouse model. Cyclin A2 deletion in oncogene-transformed mouse embryonic fibroblasts (MEF) suppressed tumor formation in immunocompromised mice. These findings were confirmed in mice with cyclin A2-deficient hepatocytes, where a delay in liver tumor formation was observed. Because cyclin A2 acts in complex with Cdk2 in the cell cycle, we explored a hypothesized role for Cdk2 dysregulation in this effect through conditional deletions of both genes. In oncogene-transformed MEFs lacking both genes, tumor formation was strongly suppressed in a manner associated with decreased proliferation, premature senescence, and error-prone recovery from serum deprivation after immortalization. Whereas loss of cyclin A2 led to a compensatory increase in Cdk1 activity, this did not occur with loss of both Cdk2 and cyclin A2. Our work offers a rationale to explore combinations of Cdk1 and Cdk2 inhibitors as a general approach in cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“As cyclin A2 deregulation is associated with aberrant cell proliferation (Gopinathan et al., 2014), these findings suggest another way in which USP7 upregulation may promote oncogenesis.”
From USP7 Is a Master Regulator of Genome Stability (2020) · cites this paper as Gopinathan et al., 2014
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A biomarker that identifies senescent human cells in culture and in aging skin in vivo.
Dimri, G. P., Lee, X., Basile, G., Acosta, M., Scott, G., Roskelley, C., Medrano, E. E., Linskens, M., Rubelj, I., & Pereira-Smith, O. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.20.9363 · Cited by 7,477
Cell cycle, CDKs and cancer: a changing paradigm
Malumbres, M., & Barbacid, M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2602 · Cited by 3,957 · cited 1×
“Aberrant expression of cyclin A2 has been detected in a variety of cancers, and deregulation of cyclin A2 appears to be closely related to chromosomal instability and tumor proliferation (3, 12, 13).”
Todaro, G. J., & Green, H. (1963) · The Journal of Cell Biology · doi:10.1083/jcb.17.2.299 · Cited by 2,747
Cyclin A is required at two points in the human cell cycle.
Pagano, M., Pepperkok, R., Verde, F., Ansorge, W. J., & Draetta, G. F. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05135.x · Cited by 1,403
Lee, E.-C., Yu, D., de Velasco, J. M., Tessarollo, L., Swing, D. A., Court, D. L., Jenkins, N. A., & Copeland, N. G. (2001) · Genomics · doi:10.1006/geno.2000.6451 · Cited by 1,180
High-efficiency deleter mice show that FLPe is an alternative to Cre-loxP
Rodríguez, C. I., Buchholz, F., Galloway, J. L., Sequerra, R., Kasper, J. S., Ayala, R., Stewart, A. F., & Dymecki, S. M. (2000) · Nature Genetics · doi:10.1038/75973 · Cited by 1,162
Cyclin a is required for the onset of DNA replication in mammalian fibroblasts
Girard, F., Strausfeld, U. P., Fernandez, A., & Lamb, N. J. C. (1991) · Cell · doi:10.1016/0092-8674(91)90293-8 · Cited by 880
Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice
Ortega, S., Priéto, I., Odajima, J., Martín, A. L., Dubus, P. R., Sotillo, R., Barbero, J. L., Malumbres, M., & Barbacid, M. (2003) · Nature Genetics · doi:10.1038/ng1232 · Cited by 798
Berthet, C., Aleem, E. A., Coppola, V., Tessarollo, L., & Kaldis, P. (2003) · Current Biology · doi:10.1016/j.cub.2003.09.024 · Cited by 665
Mouse development and cell proliferation in the absence of D-cyclins
Kozar, K., Ciemerych, M. A., Rebel, V. I., Shigematsu, H., Zagozdzon, A., Sicinska, E., Geng, Y., Yu, Q., Bhattacharya, S., Bronson, R. T., et al. (2004) · Cell · doi:10.1016/j.cell.2004.07.025 · Cited by 647
Cited by
Sorted by citations
Cell cycle proteins as promising targets in cancer therapy
Otto, T., & Siciński, P. (2017) · Nature reviews. Cancer · doi:10.1038/nrc.2016.138 · Cited by 1,931
Pyroptosis: A new frontier in cancer
Fang, Y., Tian, S., Pan, Y., Li, W., Wang, Q., Tang, Y. R., Yu, T., Wu, X., Shi, Y., Ma, P., et al. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109595 · Cited by 1,073
Targeting cell-cycle machinery in cancer
Suski, J. M., Braun, M., Strmiska, V., & Siciński, P. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.03.010 · Cited by 587
Inhibitors of cyclin-dependent kinases as cancer therapeutics.
Whittaker, S. R., Mallinger, A., Workman, P., & Clarke, P. A. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.008 · Cited by 384
Zhang, H., Deng, T., Ge, S., Liu, Y., Bai, M., Zhu, K., Fan, Q., Li, J., Ning, T., Tian, F., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0619-z · Cited by 303
RetractedHuang, H., Benzonana, L. L., Zhao, H., Watts, H. R., Perry, N. J. S., Bevan, C., Brown, R., & Ma, D. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.426 · Cited by 223
Stabilization of histone demethylase PHF8 by USP7 promotes breast carcinogenesis.
Wang, Q., Ma, S., Song, N., Li, X., Liu, L., Yang, S., Ding, X., Shan, L., Zhou, X., Su, D., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci85747 · Cited by 206
Knudsen, E. S., Kumarasamy, V. M., Nambiar, R., Pearson, J. D., Vail, P. J., Rosenheck, H. R., Wang, J., Eng, K., Bremner, R., Schramek, D., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110448 · Cited by 128
USP7 Is a Master Regulator of Genome Stability
Valles, G. J., Bezsonova, I., Woodgate, R., & Ashton, N. W. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00717 · Cited by 114
“As cyclin A2 deregulation is associated with aberrant cell proliferation (Gopinathan et al., 2014), these findings suggest another way in which USP7 upregulation may promote oncogenesis.”
BackgroundTargeting CDK12 for Cancer Therapy: Function, Mechanism, and Drug Discovery
Liu, H., Liu, K., & Dong, Z. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-2245 · Cited by 101
Brunner, S. M., Rubner, C., Kesselring, R., Martin, M. P., Griesshammer, E., Ruemmele, P., Stempfl, T., Teufel, A., Schlitt, H. J., & Fichtner‐Feigl, S. (2015) · Hepatology · doi:10.1002/hep.27728 · Cited by 101
Niu, Y., Xu, J., & Sun, T. (2019) · Journal of Cancer · doi:10.7150/jca.32628 · Cited by 102
Crncec, A., & Hochegger, H. (2019) · FEBS Letters · doi:10.1002/1873-3468.13635 · Cited by 97
WNT/β-Catenin Signaling Regulates Multiple Steps of Myogenesis by Regulating Step-Specific Targets
Suzuki, A., Pelikan, R. C., & Iwata, J. (2015) · Molecular and Cellular Biology · doi:10.1128/mcb.01180-14 · Cited by 80
Xu, S., Wu, W., Huang, H., Huang, R., Xie, L., Su, A., Liu, S., Zheng, R., Yuan, Y., Zheng, H., et al. (2019) · Aging Cell · doi:10.1111/acel.12918 · Cited by 79
Cyclin A triggers Mitosis either via the Greatwall kinase pathway or Cyclin B
Hégarat, N., Crncec, A., Rodríguez, M. F. S. P., Iturra, F. E., Gu, Y. H., Busby, O., Lang, P. F., Barr, A. R., Bakal, C., Kanemaki, M. T., et al. (2020) · The EMBO Journal · doi:10.15252/embj.2020104419 · Cited by 78
Darżynkiewicz, Z., Zhao, H., Zhang, S., Lee, M., Lee, E. Y. C., & Zhang, Z. (2015) · Oncotarget · doi:10.18632/oncotarget.4149 · Cited by 74
Liu, H., Zhang, Z., Wu, N., Guo, H., Zhang, H., Fan, D., Nie, Y., & Liu, Y. (2018) · Genes · doi:10.3390/genes9060303 · Cited by 70
The microRNAs miR-449a and miR-424 suppress osteosarcoma by targeting cyclin A2 expression
Shekhar, R., Priyanka, P., Kumar, P., Ghosh, T., Khan, M. M., Nagarajan, P., & Saxena, S. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.005778 · Cited by 70
Wang, X., Zhu, X., Zhang, H., Wei, S., Chen, Y., Chen, Y., Wang, F., Fan, X., Han, S., & Wu, G. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.01.126 · Cited by 69
Lu, X., Zhang, J., Zhang, S., Qiao, J., Qiu, M., Liu, X.-R., Chen, X., Gao, C., & Zhang, H.-H. (2021) · BMC Cancer · doi:10.1186/s12885-021-08358-7 · Cited by 56
Liu, X., Wu, J., Zhang, D., Wang, K., Duan, X., Meng, Z., & Zhang, X. (2018) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2018/7802639 · Cited by 55
Role of pyroptosis in cancer and its therapeutic regulation
Mamun, A. A., Mimi, A. A., Aziz, M. A., Zaeem, M., Ahmed, T., Munir, F., & Xiao, J. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.174444 · Cited by 53
Cancer cell cycle dystopia: heterogeneity, plasticity, and therapy
Witkiewicz, A. K., Kumarasamy, V. M., Sanidas, I., & Knudsen, E. S. (2022) · Trends in cancer · doi:10.1016/j.trecan.2022.04.006 · Cited by 52
An Integrative Human Pan-Cancer Analysis of Cyclin-Dependent Kinase 1 (CDK1)
Liu, X., Wu, H., & Liu, Z. (2022) · Cancers · doi:10.3390/cancers14112658 · Cited by 50
Application of Regulatory Cell Death in Cancer: Based on Targeted Therapy and Immunotherapy
Qi, X., Li, Q., Che, X., Wang, Q., & Wu, G. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.837293 · Cited by 48
Qiu, S., Hu, Y., & Dong, S. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108270 · Cited by 45
De Novo Molecule Design Using Molecular Generative Models Constrained by Ligand–Protein Interactions
Zhang, J., & Chen, H. (2022) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.2c00177 · Cited by 44
Eirin, A., Zhu, X.-Y., Woollard, J. R., Tang, H. R., Dasari, S., Lerman, A., & Lerman, L. O. (2019) · Stem Cells Translational Medicine · doi:10.1002/sctm.18-0171 · Cited by 43
Xu, B., Shao, Q., Xie, K., Zhang, Y., Dong, T., Xia, Y., & Tang, W. (2016) · Cellular Physiology and Biochemistry · doi:10.1159/000438637 · Cited by 43
Wu, C., Qi, X., Qiu, Z., Deng, G., & Zhong, L. (2021) · Aging · doi:10.18632/aging.203494 · Cited by 43
Analysis of potential key genes in very early hepatocellular carcinoma
Wu, M. Y., Liu, Z., Li, X., Zhang, A., Lin, D., & Li, N. (2019) · World Journal of Surgical Oncology · doi:10.1186/s12957-019-1616-6 · Cited by 42
Loss of hepatocyte cell division leads to liver inflammation and fibrosis
Dewhurst, M. R., Ow, J. R., Zafer, G., van Hul, N. K. M., Wollmann, H., Bisteau, X., Brough, D., Choi, H., & Kaldis, P. (2020) · PLOS Genetics · doi:10.1371/journal.pgen.1009084 · Cited by 42
Self-citationGao, B., Liu, X., Li, Z., Zhao, L., & Pan, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.600514 · Cited by 41
Marthandan, S., Menzel, U., Priebe, S., Groth, M., Guthke, R., Platzer, M., Hemmerich, P., Kaether, C., & Diekmann, S. (2016) · Biological Research · doi:10.1186/s40659-016-0095-2 · Cited by 39
Cyclin A2 modulates kinetochore–microtubule attachment in meiosis II
Zhang, Q.-H., Yuen, W. S., Adhikari, D., Flegg, J. A., FitzHarris, G., Conti, M., Siciński, P., Nabti, I., Marangos, P., & Carroll, J. (2017) · The Journal of Cell Biology · doi:10.1083/jcb.201607111 · Cited by 39
Lu, Y., Su, F., Yang, H., Xiao, Y., Zhang, X., Su, H., Zhang, T., Bai, Y., & Ling, X. (2021) · Cancer Biomarkers · doi:10.3233/cbm-210149 · Cited by 38
miR‑508‑3p suppresses the development of ovarian carcinoma by targeting CCNA2 and MMP7
Guo, F., Zhang, K., Li, M., Cui, L., Liu, G., Yan, Y., Tian, W., Teng, F., Zhang, Y., Gao, C., et al. (2020) · International Journal of Oncology · doi:10.3892/ijo.2020.5055 · Cited by 37
Circadian clock: Time for novel anticancer strategies?
Ercolani, L., Ferrari, A., Mei, C. D., Parodi, C., Wade, M. R., & Grimaldi, B. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.08.008 · Cited by 35
Wang, T., Zhang, W., Wang, Z., Wu, Z., Du, B., Li, L., Chen, Y., Yang, X., Hao, X., & Guo, T. (2019) · Cancer Medicine · doi:10.1002/cam4.2810 · Cited by 38
CCNA2 facilitates epithelial-to-mesenchymal transition via the integrin αvβ3 signaling in NSCLC.
Ruan, J. S., Zhou, H., Yang, L., Wang, L., Jiang, Z. S., & Wang, S. M. (2017) · PubMed Central · Cited by 36
Cyclin A2 maintains colon homeostasis and is a prognostic factor in colorectal cancer
Guo, Y., Gabola, M., Lattanzio, R., Paul, C., Pinet, V., Tang, R., Turali, H., Bremond, J., Longobardi, C., Maurizy, C., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci131517 · Cited by 33
Liu, Y., Yi, Y., Wu, W., Wu, K., & Zhang, W. (2019) · Oncology Letters · doi:10.3892/ol.2019.10371 · Cited by 31
Characterization of Dermal Stem Cells of Diabetic Patients
Ferroni, L., Gardin, C., Paola, L. D., Campo, G. C., Cimaglia, P., Bellin, G., Pinton, P., & Zavan, B. (2019) · Cells · doi:10.3390/cells8070729 · Cited by 30
Raltitrexed Inhibits HepG2 Cell Proliferation via G0/G1 Cell Cycle Arrest
Zhao, H., Zhang, Y., Sun, J., Zhan, C., & Zhao, L. (2016) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/096504016x14562725373671 · Cited by 30
Screening and Identification of Potential Prognostic Biomarkers in Adrenocortical Carcinoma
Xu, W.-H., Wu, J., Wang, J., Wan, F., Wang, H., Cao, D., Qu, Y.-Y., Zhang, H., & Ye, D. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00821 · Cited by 29
Tian, L., Chen, T., Lü, J., Yan, J., Zhang, Y., Qin, P., Ding, S., & Zhou, Y. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.631982 · Cited by 26
The comparative biochemistry of viruses and humans: an evolutionary path towards autoimmunity
Kanduc, D. (2018) · Biological Chemistry · doi:10.1515/hsz-2018-0271 · Cited by 25
Tu, X., Hong, D., Jiang, Y., Lou, Z., Wang, K., Jiang, Y., & Jin, L. (2018) · Gene · doi:10.1016/j.gene.2018.12.008 · Cited by 26
Ming, P., Cai, T., Li, J., Ning, Y., Xie, S., Tao, T., & Tang, F. (2016) · Oncotarget · doi:10.18632/oncotarget.9731 · Cited by 25
Luan, T., Zhang, T., Lv, Z., Guan, B., Xu, J., Li, J., Li, M., & Hu, S. (2021) · FEBS Open Bio · doi:10.1002/2211-5463.13140 · Cited by 23
Chen, Q., Shen, P., Ge, W., Yang, T., Wang, W.-J., Meng, L., Huang, X., Zhang, Y., Cao, S., Miao, Y., et al. (2021) · Oncogene · doi:10.1038/s41388-021-01741-5 · Cited by 24
LncRNA ENST00000539653 acts as an oncogenic factor via MAPK signalling in papillary thyroid cancer
Song, B., Li, R., Zuo, Z., Tan, J., Liu, L., Ding, D., Lu, Y., & Hou, D. (2019) · BMC Cancer · doi:10.1186/s12885-019-5533-4 · Cited by 23
Zhao, G.-X., Xu, L., Pan, H., Lin, Q.-R., Huang, M.-Y., Cai, J., Ouyang, D., & He, X. (2015) · Oncotarget · doi:10.18632/oncotarget.5731 · Cited by 22
Zhang, H.-P., Wang, Y., Ma, S., Zhang, H., Yang, A., Yang, X., Zhang, M.-H., Sun, J., Hao, Y., & Jiang, Y. (2017) · Experimental Cell Research · doi:10.1016/j.yexcr.2017.11.021 · Cited by 20
Chen, S., Zhao, Z., Wang, X., Zhang, Q., Lyu, L., & Tang, B. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.809509 · Cited by 20
Eifler, M., Uecker, R., Weisbach, H., Bogdanow, B., Richter, E., König, L., Vetter, B., Roviš, T. L., Jonjić, S., Neitzel, H., et al. (2014) · PLoS Pathogens · doi:10.1371/journal.ppat.1004514 · Cited by 19
Luo, L.-L., Zhao, L., Wang, Y., Tian, X.-P., Xi, M., Shen, J.-X., He, L.-R., Li, Q.-Q., Liu, S.-L., Zhang, P., et al. (2015) · Scientific Reports · doi:10.1038/srep17336 · Cited by 19
Valeri, A., Chiricosta, L., Calcaterra, V., Biasin, M., Cappelletti, G., Carelli, S., Zuccotti, G., Bramanti, P., Pelizzo, G., Mazzon, E., et al. (2021) · Cells · doi:10.3390/cells10092189 · Cited by 18
Ke, X.-G., Xiong, Y., Yu, B., Yuan, C. G., Chen, P.-Y., Yang, Y., & Wu, H. (2022) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2022.109805 · Cited by 18
Mesenchymal Stem Cells from Cervix and Age: New Insights into CIN Regression Rate
Orciani, M., Caffarini, M., Lazzarini, R., Carpini, G. D., Tsiroglou, D., Primio, R. D., & Ciavattini, A. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/1545784 · Cited by 19
IGFBP6 regulates vascular smooth muscle cell proliferation and morphology via cyclin E–CDK2
Wang, Z., Qi, Y., Wang, R., Wu, W., Li, Z., Wang, M., Liu, R., Zhang, C., Li, W., & Wang, S. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.29762 · Cited by 17
Liu, B., Xiao, Y., Li, H., Zhang, A., Meng, L., Lü, F., Zhao, Z., Ni, X., Fan, B., Zhang, X., et al. (2020) · BioMed Research International · doi:10.1155/2020/6954793 · Cited by 17
Liu, Z., Yu, Y. F., Kang, W., Chen, F., Yan, F., Ma, B., & Ge, S. (2022) · Composites Part B Engineering · doi:10.1016/j.compositesb.2022.110186 · Cited by 17
Advani, D., & Kumar, P. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04130-7 · Cited by 16
Bioinformatics screening of biomarkers related to liver cancer
Wang, Y., Tian, Z.-B., & Tang, X.-Q. (2021) · BMC Bioinformatics · doi:10.1186/s12859-021-04411-1 · Cited by 16
Expression and Significance of LncRNA-MINCR and CDK2 mRNA in Primary Hepatocellular Carcinoma
Lian, J., Zhang, X., Lu, Y., Hao, S., Zhang, Z., & Yang, Y. (2019) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/1386207322666190404151020 · Cited by 15
Chen, C., Zhang, R., Ma, L., Li, Q., Zhao, Y., Zhang, G., Zhang, D., Li, W., Cao, S., Wang, L., et al. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15825 · Cited by 14
Fu, H., Zhang, Y., Chen, Y., Chen, J., & Chen, P. (2020) · Molecular Medicine Reports · doi:10.3892/mmr.2020.11684 · Cited by 14
Compound K is a potential clinical anticancer agent in prostate cancer by arresting cell cycle
Liu, M., Zhang, Y., Zhang, A., Deng, Y., Gao, X., Wang, J., Wáng, Y., Wang, S., Liu, J., Chen, S., et al. (2022) · Phytomedicine · doi:10.1016/j.phymed.2022.154584 · Cited by 14
Ding, C., Yang, X. F., Li, S., Zhang, E., Fan, X., Huang, L., He, Z., Sun, J. P., Ma, J., Zang, L., et al. (2023) · Cancer Cell International · doi:10.1186/s12935-023-02897-8 · Cited by 14
He, J., Zhao, Y., Zhang, Y., Zhang, Z., Li, D., & Xu, Q. (2024) · Cellular Signalling · doi:10.1016/j.cellsig.2024.111098 · Cited by 13
Kakar, M., Mehboob, M., Akram, M., Shah, M., Shakir, Y., Ijaz, H., Aziz, U., Ullah, Z., Ahmad, S., Ali, S., et al. (2022) · BioMed Research International · doi:10.1155/2022/4237633 · Cited by 11
LncRNA FAM66C inhibits pancreatic cancer progression by sponging miR-574-3p
Zhu, J., Zhu, S. Z., Yu, Q., & Wu, Y. (2020) · Translational Cancer Research · doi:10.21037/tcr.2020.02.24 · Cited by 13
Gatfaoui, S., Issaoui, N., Noureddine, O., Roisnel, T., & Marouani, H. (2021) · Journal of the Iranian Chemical Society · doi:10.1007/s13738-021-02195-y · Cited by 12
GPR27 Regulates Hepatocellular Carcinoma Progression via MAPK/ERK Pathway
Wang, H., Du, D., Huang, J., Wang, S., He, X., Yuan, S., & Xiao, J. (2022) · Cancer Management and Research · doi:10.2147/cmar.s335749 · Cited by 13
Cyclin A2 regulates erythrocyte morphology and numbers
Jayapal, S. R., Ang, H. Y.-K., Wang, C. Q., Bisteau, X., Caldez, M. J., Xuan, G. X., Yu, W., Tergaonkar, V., Osato, M., Lim, B., et al. (2016) · Cell Cycle · doi:10.1080/15384101.2016.1234546 · Cited by 12
Jin, B., Kim, H.-J., Kim, E.-Y., Chung, T., Ha, K., & An, H. (2019) · Nutrients · doi:10.3390/nu11092203 · Cited by 12
Mao, W., Huai, Y., An, L., Wang, X., Ru, K., Patil, S., Zhang, W., Ran, F., Chen, Z., & Qian, A. (2023) · Space Science & Technology · doi:10.34133/space.0104 · Cited by 11
Liang, K., Wang, Q., Qiu, L., Gong, X., Chen, Z., Zhang, H., Ding, K., Liu, Y., Wei, J., Lin, S., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242115658 · Cited by 12
Striatal ZBTB16 Is Associated With Cognitive Deficits in Alzheimer Disease Mice
Lee, S.-J., Kim, T. K., Choi, J. E., Kim, H.-S., & Im, H. (2022) · International Neurourology Journal · doi:10.5213/inj.2244254.127 · Cited by 9
Dou, W., Xie, J., Chen, J., Zhou, J., Xu, Z., Wang, Z., & Zhu, Q. (2022) · Cell Cycle · doi:10.1080/15384101.2022.2135621 · Cited by 8
Screening of biomarkers for liver adenoma in low-dose-rate γ-ray-irradiated mice
Sugihara, T., Tanaka, S., Braga-Tanaka, I., Murano, H., Nakamura-Murano, M., & Komura, J. (2018) · International Journal of Radiation Biology · doi:10.1080/09553002.2018.1439193 · Cited by 7
Alternative splicing dynamically regulates common carp embryogenesis under thermal stress
Hu, S., Tian, G., Bai, Y., Qu, A., He, Q., Chen, L., & Xu, P. (2024) · BMC Genomics · doi:10.1186/s12864-024-10838-6 · Cited by 6
Sankar, R., & Sharmila, T. M. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.108010 · Cited by 6
Lei, X., Qiu, L., Chen, Q., Liao, L., Yu, P., Wu, W., Zhu, Z., Li, C., Lin, G., Zhuang, Z., et al. (2025) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2025.110216 · Cited by 6
Lu, S., Hua, J., Liu, J., Wei, M., Liang, C., Meng, Q., Zhang, B., Yu, X., Wang, W., & Xu, J. (2022) · Translational Oncology · doi:10.1016/j.tranon.2022.101524 · Cited by 6
Sun, X., Song, J., Lu, C., Sun, X., Yue, H., Bao, H., Wang, S., & Zhong, X. (2023) · PubMed Central · Cited by 6
Oshchepkov, M., Владимирович, К. Л., Kalistratova, A. V., Ivanova, M., Sherstyanykh, G. D., Dudina, P. V., Antonov, A., Cherkasova, A., & Akimov, M. (2022) · Molecules · doi:10.3390/molecules27113616 · Cited by 6
Ginkgetin inhibits the proliferation and migration of lung cancer cells via FAK/STAT3/AKT pathway
Sun, L., Chen, W., Yuan, W., Huang, Q., Yang, H., Zhang, W., Tang, J., & Hu, P. (2025) · Molecular Biology Reports · doi:10.1007/s11033-025-10540-0 · Cited by 5
Induction of Mitosis Delay and Apoptosis by CDDO-TFEA in Glioblastoma Multiforme
Tsai, T., Lieu, A., Huang, T., Kwan, A., Lin, C., & Hsu, Y. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.756228 · Cited by 5
Yu, Z., Wang, L., Ji, C., Sun, Y., & Shao, F. (2023) · Functional & Integrative Genomics · doi:10.1007/s10142-023-01103-2 · Cited by 5
Analysis of two-gene signatures and related drugs in small-cell lung cancer by bioinformatics
Li, Y., Zhou, X., & Lyu, Z. (2023) · Open Medicine · doi:10.1515/med-2023-0806 · Cited by 4
Multiplexed Profiling of CDK Kinase Activities in Tumor Biopsies with Fluorescent Peptide Biosensors
Royet, C., Diot, S., Onofre, M., Lecki, L., Pastore, M., Reynès, C., Lorcy, F., Szablewski, V., Serre, I., & Morris, M. C. (2024) · ACS Sensors · doi:10.1021/acssensors.4c00139 · Cited by 5
Upregulated expression of PTTG1 is associated with progression of pancreatic cancer
He, Y., Du, Z., Peng, H., Reddy, A. V., & Cao, P. (2024) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-23-979 · Cited by 3
de Albuquerque, P. B. S., Ramos, L. F. S., Dantas, M. D. F. F. D. C., Othmar, F. D. S., Galúcio, J. M. P., da Costa, K. S., Costa, M. J. F., Rodrigues, N. E. R., de Lima, L. R. A., & Sette‐de‐Souza, P. H. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.137909 · Cited by 3
Targeted Therapies in Lung Cancers: Current Landscape and Future Prospects
Feng, X., Ding, W., Ma, J., Liu, B., & Yuan, H. (2021) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/1574892816666210615161501 · Cited by 3
Regulation of Cell Cycle During Liver Regeneration
Nevzorova, Y. A., & Trautwein, C. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-420128-6.00011-7 · Cited by 3
Fang, W., Chen, C., Nie, M., Liu, Q., Huang, T., Gao, C., Liu, Y., Zhou, X., & Wang, X. (2026) · Cell Communication and Signaling · doi:10.1186/s12964-026-02737-y · Cited by 2
Identification of novel potential biomarkers in hepatocarcinoma cancer; a transcriptome analysisPreprint
Kakar, M. U., Mehboob, M. Z., Akram, M. B., Iqbal, I., Ijaz, H. W., Aziz, U., Lodhi, A. F., Rasheed, M., Deng, Y., & Rong-Ji, D. A. I. (2021) · Research Square · doi:10.21203/rs.3.rs-154350/v3 · Cited by 2
Metadata
- Authors
- Gopinathan, L., Tan, S. L. W., Padmakumar, V. C., Coppola, V., Tessarollo, L., & Kaldis, P.
- Affiliations
- Agency for Science, Technology and Research (SG)
- National Cancer Institute (US)
- Corresponding author
- Kaldis, Philipp
- Venue
- Cancer Research
- Published
- 2014-07-14
- Volume
- 74
- Issue
- 14
- Pages
- 3870-3879
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- PMC
- PMC4102624
- OpenAlex
- W2166466732
- Cited by
- 123
- References
- 36
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 11 · 2023: 6 · 2022: 15 · 2021: 22 · 2020: 14 · 2019: 16 · 2018: 9 · 2017: 5 · 2016: 7 · 2015: 8 · 2014: 2
- FWCI
- 3.54
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- Funders
- American Association for Cancer Research
- National Institutes of Health
- Institute of Molecular and Cell Biology
- Biomedical Research Council
- National Cancer Institute (Z01SC010367)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Microtubule and mitosis dynamics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- cyclin A2, CDK2, CDK1, cell cycle, carcinogenesis, cell proliferation, premature senescence, hepatocellular carcinoma, cell cycle inhibitors, conditional knockout mice
- MeSH terms
- Animals, Cell Transformation, Neoplastic, Disease Models, Animal, Enzyme Activation, Fibroblasts, Liver Neoplasms, CDC2 Protein Kinase, Cellular Senescence, Gene Deletion, Tumor Burden, Cell Proliferation, Cyclin-Dependent Kinase 2, Mice, Gene Knockdown Techniques, Cyclin A2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review